WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317952
CAS#: 226700-81-8 (calcium)
Description: Fosamprenavir Calcium Salt is a HIV protease inhibitor that is water soluble prodrug of amprenavir. Fosamprenavir Calcium is the calcium salt form of fosamprenavir, prodrug of amprenavir with antiviral property. Fosamprenavir is converted to amprenavir by cellular phosphatases in the epithelial cells of the intestine.
Hodoodo Cat#: H317952
Name: Fosamprenavir Calcium
CAS#: 226700-81-8 (calcium)
Chemical Formula: C25H34CaN3O9PS
Exact Mass: 0.00
Molecular Weight: 623.670
Elemental Analysis: C, 48.15; H, 5.49; Ca, 6.43; N, 6.74; O, 23.09; P, 4.97; S, 5.14
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Fosamprenavir Calcium; Lexiva; GW433908G; Amprenavir phosphate calcium; UNII-ID1GU2627N; GW 433908; GW 433908G; GW 908; GW-433908; GW-433908G; GW-908;
IUPAC/Chemical Name: calcium;[(2R,3S)-1-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-[[(3S)-oxolan-3-yl]oxycarbonylamino]-4-phenylbutan-2-yl] phosphate
InChi Key: PMDQGYMGQKTCSX-HQROKSDRSA-L
InChi Code: InChI=1S/C25H36N3O9PS.Ca/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21;/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32);/q;+2/p-2/t21-,23-,24+;/m0./s1
SMILES Code: CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)([O-])[O-])S(=O)(=O)C3=CC=C(C=C3)N.[Ca+2]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 226700-81-8 (calcium); 226700-79-4 (free)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 623.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ross LL, Cotton MF, Cassim H, Voronin E, Givens N, Sievers J, Cheng KY; APV29005 & APV20002 Pediatric Study Groups. Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens. Open AIDS J. 2015 May 15;9:38-44. doi: 10.2174/1874613601509010038. eCollection 2015. PubMed PMID: 26157536; PubMed Central PMCID: PMC4484231.
2: Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrob Agents Chemother. 2014 Nov;58(11):6696-700. doi: 10.1128/AAC.03282-14. Epub 2014 Aug 25. PubMed PMID: 25155604; PubMed Central PMCID: PMC4249430.
3: Barbour AM, Gibiansky L, Wire MB. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. J Clin Pharmacol. 2014 Feb;54(2):206-14. doi: 10.1002/jcph.205. Epub 2013 Nov 5. PubMed PMID: 25272370.
4: Wood R, Gathe JC, Givens N, Sedani S, Cheng K, Sievers J. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients. HIV Clin Trials. 2013 Sep-Oct;14(5):183-91. doi: 10.1310/hct1405-183. PubMed PMID: 24144895.
5: Torres HA, Arduino RC. Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther. 2007 Jun;5(3):349-63. Review. PubMed PMID: 17547501.
